Original ArticleFibrinogen and the Severity of Coronary Atherosclerosis among Adults with and without Statin Treatment: Lipid as a mediator
Introduction
Coronary artery disease (CAD) due to atherosclerosis is the major cause of associated morbidity and mortality in the world. Current perspectives regard low grade chronic inflammation as well as imbalanced lipid metabolism as critical contributors for atherosclerosis progression and plaque instability [1], [2]. This recognition has stimulated the evaluation of different inflammatory markers as potential predictors of cardiovascular risk.
Fibrinogen is a coagulation/inflammatory biomarker closely related to cardiovascular risk. In addition to its essential properties as a cofactor of platelet aggregation and as the main substrate for thrombin in the plasmatic coagulation, fibrinogen has been suggested to play a pivotal role in the initial and advanced stages of atherosclerosis [3], [4]. Early evidence from previous decades pointed to a strong association between fibrinogen and early signs of atherosclerosis in asymptomatic individuals [5], [6]. Also, several investigations have proposed fibrinogen as an important risk factor for future cardiovascular events in patients with CAD [7], [8], [9] and in apparently healthy individuals [10], [11]. Although fibrinogen has been suggested to be a predictor of cardiovascular risk, the underlying mechanism has not yet been well-elucidated.
One possible mechanism is that fibrinogen, an acute phase protein, reflects the inflammatory state of the vascular wall [12], however, this notion may not fully account for the risk of fibrinogen in the development of CAD. Previous studies implied that increased basal fibrinogen expression could enhance cholesterol synthesis in HepG2 cells [13] and elevated plasma fibrinogen was associated with increased lipid peroxidation [14]. Meanwhile, our recent data suggested a positive association between fibrinogen and the major cholesterol regulator, proprotein convertase subtilisin/kexin type 9 in the status of atherosclerosis [15]. Furthermore, the genetic study revealed that the expression of gene clusters which control inflammatory processes and lipid metabolism was an interrelated response to metabolic overload [16]. Nonetheless, clinical data regarding the interplay between fibrinogen and lipids in coronary atherosclerosis is largely unavailable. In light of the preceding discussion, it is plausible to hypothesise that there may be an interaction between fibrinogen and lipids and the latter may be potential mediators in coronary atherosclerosis.
Therefore, in this large cohort of Chinese individuals (n=4748) undergoing diagnostic or interventional coronary angiography, we sought to investigate the interaction between fibrinogen and lipids with the severity of coronary atherosclerosis assessed by Gensini score (GS), and further evaluate whether the plasma lipids partly mediate the association between fibrinogen and high GS.
Section snippets
Study Design and Population
The study protocol complied with the Declaration of Helsinki, and was approved by the hospital ethics review board (FuWai Hospital & National Center for Cardiovascular Diseases, Beijing, China). All patients gave their informed, written consent.
This was a hospital-based cross-sectional study. We enrolled 4748 consecutive subjects with suspected coronary atherosclerosis for elective coronary angiography in our institution from April 2011 to October 2014. Complete medical history was taken from
Baseline Clinical Characteristics
Diagrammatic presentations of our sample size are shown in Figure 1. Our total sample size was 4748 and consisted of 3557 and 1191 participants with and without statin treatment, respectively. The baseline demographic, clinical characteristics and laboratory data are summarised in Table 1. This study population consisted of patients with an average age of 58±10 years, and 70.8% of this population was male. The prevalent CAD was 82.9%. The median GS level was 21(7-44) and the mean fibrinogen
Discussion
To the best of our knowledge, this is the first large-scale study evaluating the interplay between fibrinogen and lipids in relation to the severity of coronary atherosclerosis. The novel finding of the present study is that the relationship between fibrinogen and severity of coronary atherosclerosis appears to be enhanced by the increased atherogenic lipid levels, which mediated around 24% of this effect.
Fibrinogen is a soluble glycoprotein with a molecular weight of 340 kDa which consists of
Declaration of Interest
The authors have no conflict of interests.
Acknowledgments
This work was partly supported by National Natural Scientific Foundation (81070171, 81241121), Specialized Research Fund for the Doctoral Program of Higher Education of China (20111106110013), Capital Special Foundation of Clinical Application Research (Z121107001012015), Capital Health Development Fund (2011400302), and Beijing Natural Science Foundation (7131014) awarded to Dr. Jian-Jun Li, MD, PhD.
References (33)
- et al.
Longitudinal assessment of fibrinogen in relation to subclinical cardiovascular disease: the CARDIA study
J Thromb Haemost.
(2010) - et al.
Elevated fibrinogen levels and subsequent subclinical atherosclerosis: the CARDIA Study
Atherosclerosis.
(2009) - et al.
Relation of fibrinogen level with cardiovascular events in patients with coronary artery disease
Am J Cardiol.
(2013) - et al.
Aggregate risk score based on markers of inflammation, cell stress, and coagulation is an independent predictor of adverse cardiovascular outcomes
J Am Coll Cardiol.
(2013) - et al.
Fibrinogen synthesis is increased in cachectic patients with chronic heart failure
Int J Cardiol.
(2008) - et al.
Relationship between lipid peroxidation and plasma fibrinogen in middle-aged men
Thromb Res.
(2000) - et al.
Relation of circulating PCSK9 concentration to fibrinogen in patients with stable coronary artery disease
J Clin Lipidol.
(2014) A more meaningful scoring system for determining the severity of coronary heart disease
Am J Cardiol.
(1983)- et al.
The relative kinetics of clotting and lysis provide a biochemical rationale for the correlation between elevated fibrinogen and cardiovascular disease
J Thromb Haemost.
(2007) - et al.
Relation of fibrinogen to cardiovascular events is independent of preclinical cardiovascular disease: the Strong Heart Study
Am Heart J.
(2003)
Risk factors for cardiovascular event recurrence in the Atherosclerosis Risk in Communities (ARIC) study
Am Heart J.
A new method of scoring coronary angiograms to reflect extent of coronary atherosclerosis and improve correlation with major risk factors
Am Heart J.
Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study
Lancet.
Analysis of circulating cholesterol levels as a mediator of an association between ABO blood group and coronary heart disease
Circ Cardiovasc Genet.
C-Reactive protein concentrations and angiographic characteristics of coronary lesions
Clin Chem.
ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)
Eur Heart J.
Cited by (10)
Correlation between fibrinogen and coronary heart disease
2022, Zhongguo Dongmai Yinghua Zazhi
- 1
The first two authors contributed equally.